ALPHA1-ANTITRYPSIN DEFICIENCY
Clinical trials for ALPHA1-ANTITRYPSIN DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ALPHA1-ANTITRYPSIN DEFICIENCY trials appear
Sign up with your email to follow new studies for ALPHA1-ANTITRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to halt liver damage in genetic disease
Disease control Recruiting nowThis study is testing a drug called fazirsiran for people with liver disease caused by Alpha-1 antitrypsin deficiency. The drug aims to reduce the buildup of an abnormal protein that causes liver scarring. About 50 adults with early-stage liver scarring will receive either the dr…
Matched conditions: ALPHA1-ANTITRYPSIN DEFICIENCY
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Breakthrough trial aims to reverse liver damage in genetic disorder
Disease control Recruiting nowThis study is testing whether an investigational drug called fazirsiran can reduce liver scarring (fibrosis) in people with Alpha-1 antitrypsin deficiency, a genetic condition that can damage the liver and lungs. About 160 adults with moderate to advanced liver scarring will rece…
Matched conditions: ALPHA1-ANTITRYPSIN DEFICIENCY
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Landmark study tracks hidden liver damage in genetic disorder
Knowledge-focused Recruiting nowThis study aims to learn how liver disease naturally progresses over 5 years in 500 adults with Alpha-1 antitrypsin deficiency (AATD), a genetic condition. Researchers will observe participants without giving any treatment, tracking liver scarring, lung function, and overall heal…
Matched conditions: ALPHA1-ANTITRYPSIN DEFICIENCY
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:01 UTC